Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

M.E. Pavel, S. Singh, J.R. Strosberg, L. Bubuteishvili-Pacaud, E. Degtyarev, M.P. Neary, C. Carnaghi, J. Tomasek, E. Wolin, M. Raderer, H. Lahner, J.W. Valle, R. Pommier, E. Van Cutsem, M.E.T. Tesselaar, G.D. Fave, R. Buzzoni, M. Hunger, J. Eriksson, D. CellaJ.-F. Ricci, N. Fazio, M.H. Kulke, J.C. Yao

Research output: Contribution to journalArticlepeer-review

Cite this